Bioventus (BVS) to Release Quarterly Earnings on Tuesday

Bioventus (NYSE:BVS) is set to release its earnings data before the market opens on Tuesday, November 5th. Analysts expect Bioventus to post earnings of $0.06 per share for the quarter. Bioventus has set its FY 2024 guidance at 0.360-0.420 EPS.

Bioventus (NYSE:BVS) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.07 by $0.12. The firm had revenue of $151.22 million for the quarter, compared to analyst estimates of $137.70 million. Bioventus had a negative net margin of 7.82% and a positive return on equity of 14.39%. During the same period in the prior year, the business posted $0.14 EPS. On average, analysts expect Bioventus to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Bioventus Trading Up 2.6 %

Shares of NYSE:BVS traded up $0.35 during mid-day trading on Wednesday, reaching $13.66. 98,684 shares of the company were exchanged, compared to its average volume of 387,385. The firm has a market cap of $1.11 billion, a price-to-earnings ratio of -20.70 and a beta of 0.90. The company has a debt-to-equity ratio of 1.82, a current ratio of 1.33 and a quick ratio of 0.96. Bioventus has a 1 year low of $3.36 and a 1 year high of $13.72. The firm’s 50-day simple moving average is $11.35 and its 200 day simple moving average is $8.01.

Insiders Place Their Bets

In related news, Director John A. Bartholdson acquired 25,500 shares of Bioventus stock in a transaction dated Monday, August 19th. The shares were acquired at an average cost of $8.55 per share, for a total transaction of $218,025.00. Following the completion of the purchase, the director now owns 6,939,357 shares in the company, valued at approximately $59,331,502.35. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director John A. Bartholdson acquired 80,000 shares of the firm’s stock in a transaction dated Friday, August 16th. The stock was acquired at an average price of $8.55 per share, for a total transaction of $684,000.00. Following the purchase, the director now owns 6,913,857 shares of the company’s stock, valued at $59,113,477.35. This represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director John A. Bartholdson bought 25,500 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The shares were purchased at an average price of $8.55 per share, for a total transaction of $218,025.00. Following the completion of the purchase, the director now directly owns 6,939,357 shares of the company’s stock, valued at approximately $59,331,502.35. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders own 32.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on BVS shares. Canaccord Genuity Group lifted their price objective on Bioventus from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Tuesday, August 13th. Craig Hallum lifted their target price on Bioventus from $12.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, September 27th.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.